Syncromune
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.
Domain
syncromune.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$111.8M
Founded
2019
Tech Stack (35 technologies)
Frequently Asked Questions
What technologies does Syncromune use?+
Syncromune uses 35 technologies including Contact Form 7, Elementor, Font Awesome.
What industry is Syncromune in?+
Syncromune operates in the Biotechnology industry.
Where is Syncromune based?+
Syncromune is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026